SOFT TISSUE & BONE SARCOMA GROUP

EORTC 1809 – STRASS II – A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (RPS)

Retroperitoneal sarcoma is a very rare tumour, occurring in 0.5 to 1.0 per 100,000 of the population. Diagnosis and treatment are challenging. The standard of care consists currently of surgery. Overall patient survival at 5 years following surgery is between
60 and 70%.

The EORTC 1809 STRASS II study is the first official trial looking into potential benefits of chemotherapy before surgery to improve disease control and survival in patients burdened by this rare cancer.

SOFT TISSUE & BONE SARCOMA GROUP

EORTC Cancer Research Fund

EORTC 1809 – STRASS II – A randomized phase III study of neoadjuvant chemotherapy followed by surgery versus surgery alone for patients with High Risk RetroPeritoneal Sarcoma (RPS)

Retroperitoneal sarcoma is a very rare tumour, occurring in 0.5 to 1.0 per 100,000 of the population. Diagnosis and treatment are challenging. The standard of care consists currently of surgery. Overall patient survival at 5 years following surgery is between
60 and 70%.

The EORTC 1809 STRASS II study is the first official trial looking into potential benefits of chemotherapy before surgery to improve disease control and survival in patients burdened by this rare cancer.

Clinical Trial

Clinical Trial Phase

Phase III

Arrow

Cancer type

EORTC Cancer Research Fund Cancer Type

Sarcoma

Arrow

Set up

Set-Up

EORTC & Intergroups

Arrow

Status

Status

Recruiting

Clinical trial:

Clinical Trial Phase

Phase III

Down Arrow

Cancer type:

EORTC Cancer Research Fund Cancer Type

Sarcoma

Down Arrow

Set up:

Set-Up

EORTC & Intergroups

Down Arrow

Status:

Status

Recruiting

KEY STUDY MILESTONES

KEY STUDY MILESTONES

A word from…

Study Coordinators
& Partners

Patients

A word from…

Study Co-ordinators & Partners

Patients

STUDY STATUS

Patient recruitment

*Updated February 2023

STUDY STATUS

Patient recruitment

*Updated February 2023

STUDY STATUS

To view the Study Status map, please flip your phone horizontally:

Do you have any question on the EORTC STRASS II clinical trial?

Do you have any question on the EORTC STRASS II clinical trial?

FUNDING PARTNERS

International grants

National grants

EORTC Cancer Research Fund anticancerfund logo 500x190 2022 e1657713223361
Climbers Against Cancer
Sarcoma UK - Logo
Cancer Research UK
Novo Nordisk DK - Logo

FUNDING PARTNERS

International grants

EORTC Cancer Research Fund anticancerfund logo 500x190 2022 e1657713223361
Climbers Against Cancer

National grants

Sarcoma UK - Logo
Cancer Research UK
Novo Nordisk DK - Logo